Study of LBL-024 alone or with LBL-007 or toripalimab for advanced melanoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug, LBL-024, either by itself or combined with another drug (LBL-007 or toripalimab) in people with advanced melanoma. The goal is to see if these combinations can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced melanoma that has at least one tumor that can be measured on scans.
- You must be willing to use effective birth control during the study and for 6 months after treatment.
- You must not have an active infection, severe heart or blood vessel disease, or an autoimmune disease that is active or likely to come back.
- You must not have had a live vaccine in the last 4 weeks.
- You must not have had surgery that could affect your participation in the 4 weeks before starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called LM103 for people with advanced melanoma who have already tried several standard treatments, including immunotherapy. The goal is to see if LM103 can help shrink tumors when other treatments have stopped working.
This trial tests a new drug (BT02) for advanced melanoma that has stopped responding to earlier treatments. The goal is to see if it is safe and may help shrink tumors.
This trial tests LBL-024 in people with advanced cancer to see how it works and how safe it is. You may consider it if you are well enough for study visits and have time to complete at least about 12 weeks of follow-up.
This trial tests a combination of three drugs (interferon, an immunotherapy drug called toripalimab, and an anti-cancer drug called anlotinib) in people with advanced melanoma that cannot be removed with surgery. The goal is to see if this combination can help shrink or control the cancer.
This study tests a new drug called LM-168, either alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that haven't responded to standard treatments. It aims to see if this combination is safe and effective, and may offer a new option when others have stopped working.
This early trial tests CBL0137 along with ipilimumab and nivolumab (two immune-based cancer medicines) in people with stage III or possibly stage IV melanoma that can be biopsied. It may help shrink melanoma and improve immune control, while also learning how safe and effective this combination is.
Hear when a new Advanced Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.